Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease / Atividade da Calicreína Tecidual Humana na Doença Coronariana Crônica Estável Angiograficamente Documentada

AbstractBackground:Human tissue kallikrein (hK1) is a key enzyme in the kallikrein–kinin system (KKS). hK1-specific amidase activity is reduced in urine samples from hypertensive and heart failure (HF) patients. The pathophysiologic role of hK1 in coronary artery disease (CAD) remains unclear.Objective:To evaluate hK1-specific amidase activity in the urine of CAD patientsMethods:Sixty-five individuals (18–75 years) who underwent cardiac catheterism (CATH) were included. Random midstream urine samples were collected immediately before CATH. Patients were classified in two groups according to the presence of coronary lesions: CAD (43 patients) and non-CAD (22 patients). hK1 amidase activity was estimated using the chromogenic substrate D-Val-Leu-Arg-Nan. Creatinine was determined using Jaffé’s method. Urinary hK1-specific amidase activity was expressed as µM/(min · mg creatinine) to correct for differences in urine flow rates.Results:Urinary hK1-specific amidase activity levels were similar between CAD [0.146 µM/(min ·mg creatinine)] and non-CAD [0.189 µM/(min . mg creatinine)] patients (p = 0.803) and remained similar to values previously reported for hypertensive patients [0.210 µM/(min . mg creatinine)] and HF patients [0.104 µM/(min . mg creatinine)]. CAD severity and hypertension were not observed to significantly affect urinary hK1-specific amidase activity.Conclusion:CAD patients had low levels of urinary hK1-specific amidase activity, suggesting that renal KKS activity may be reduced in patients with this disease.

ResumoFundamento:A calicreína tecidual humana (hK1) é enzima-chave do sistema calicreína-cinina (SCC). A atividade amidásica da hK1 está reduzida na urina de pacientes com hipertensão e insuficiência cardíaca (IC); seu papel na doença arterial (DAC) coronariana ainda não está esclarecido.Objetivo:Avaliar a atividade amidásica da hK1 na urina de pacientes com DAC.Métodos:Sessenta e cinco indivíduos (18 a 75 anos) que se submeteram ao cateterismo cardíaco (CAT) coletaram amostra do jato médio de urina imediatamente antes do CAT. Baseando-se na presença de lesões coronarianas, os pacientes eram classificados em dois grupos: DAC (43 pacientes) e sem DAC (22 indivíduos). A atividade amidásica da hK1 foi estimada com o substrato cromogênico D-Val-Leu-Arg-Nan. Creatinina foi determinada pelo método de Jaffé. A atividade amidásica específica da hK1 urinária foi expressa em µM/(min . mg de creatinina) para corrigir diferenças no fluxo urinário.Resultados:A atividade amidásica da hK1 urinária foi semelhante entre os pacientes com DAC [0,146 µM/(min . mg de creatinina)] e aqueles sem DAC [0,189 µM/(min . mg de creatinina)] (p = 0,803), e permaneceu entre os baixos valores previamente publicados para pacientes com hipertensão primária [0,210 µM/(min . mg de creatinina)] e para aqueles com IC [0,104 µM/(min . mg de creatinina)], respectivamente. Nenhum efeito estatisticamente significativo da gravidade da DAC e da hipertensão sobre a atividade amidásica da hK1 urinária foi observado.Conclusão:A atividade amidásica da hK1 na urina estava reduzida nos pacientes com DAC, o que pode sugerir que a atividade do SCC renal esteja reduzida nessa doença.

Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease.

BACKGROUND: Human tissue kallikrein (hK1) is a key enzyme in the kallikrein-kinin system (KKS). hK1-specific amidase activity is reduced in urine samples from hypertensive and heart failure (HF) patients. The pathophysiologic role of hK1 in coronary artery disease (CAD) remains unclear. OBJECTIVE: To evaluate hK1-specific amidase activity in the urine of CAD patientsMethods:Sixty-five individuals (18-75 years) who underwent cardiac catheterism (CATH) were included. Random midstream urine samples were collected immediately before CATH. Patients were classified in two groups according to the presence of coronary lesions: CAD (43 patients) and non-CAD (22 patients). hK1 amidase activity was estimated using the chromogenic substrate D-Val-Leu-Arg-Nan. Creatinine was determined using Jaffé's method. Urinary hK1-specific amidase activity was expressed as µM/(min · mg creatinine) to correct for differences in urine flow rates. RESULTS: Urinary hK1-specific amidase activity levels were similar between CAD [0.146 µM/(min ·mg creatinine)] and non-CAD [0.189 µM/(min . mg creatinine)] patients (p = 0.803) and remained similar to values previously reported for hypertensive patients [0.210 µM/(min . mg creatinine)] and HF patients [0.104 µM/(min . mg creatinine)]. CAD severity and hypertension were not observed to significantly affect urinary hK1-specific amidase activity. CONCLUSION: CAD patients had low levels of urinary hK1-specific amidase activity, suggesting that renal KKS activity may be reduced in patients with this disease.

Obstrução extrínseca do tronco da coronária esquerda causada por dilatação da artéria pulmonar associada à esquistossomíase / Extrinsic obstruction of the left main coronary artery due to pulmonary artery dilation associated with schistosomiasis

Relatamos o caso de um paciente portador de hipertensão pulmonar de origem esquistossomótica, que procurou pronto atendimento por apresentar quadro de dor torácica em repouso. A apresentação clínica e os demais dados referentes ao caso levantaram a suspeita de insuficiência coronariana aguda, e foi diagnosticada uma obstrução grave do tronco da coronária esquerda. O relato do caso teve por objetivo destacar a necessidade do diagnóstico diferencial da queixa de dor torácica nestes pacientes e ressaltar a opção da intervenção coronariana percutânea como tratamento eficaz e seguro neste cenário.

This report describes a patient with pulmonary hypertension secondary to schistosomiasis, who sought emergency care due to chest pain at rest. The clinical presentation and other information related to the case raised the suspicion of acute coronary failure, and a severe obstruction was identified in the left main coronary artery. The case report aimed to highlight the need for a differential diagnosis of chest pain complaints in these patients, and emphasizes the choice of percutaneous coronary intervention as an effective and safe treatment in this scenario.

Seguimento de 12 meses de pacientes complexos tratados com stentsfarmacológicos liberadores de everolimus XIENCE V® na prática diária – resultados do registro brasileiro BRAVO / Twelve-month follow-up of complex patients treated with the Xience V™ everolimus drug-eluting stents in daily practice – results of the BRAVO Brazilian Registry

O stent liberador de everolimus XIENCE V® é um stent farmacológico de nova geração que incorpora uma plataforma de cromo-cobalto de baixo perfil (81 m) e um polímero de elevada biocompatibilidade (fluoropolímero), o qual carreia e controla a liberação do fármaco everolimus. Estudos recentes demonstram segurança e eficácia sustentadas do dispositivo XIENCE V® no tratamento de populações da prática clínica. Nosso objetivo foi reportar resultados clínicos de 12 meses do protocolo brasileiro BRAVO. Métodos: O registro BRAVO foi um estudo prospectivo, não randomizado, de braço único, multicêntrico (25centros), que avaliou os resultados clínicos tardios de 535 pacientes minimamente selecionados, tratados com o stent farmacológico XIENCE V®.Resultados: Cerca de 40% dos pacientes tinham diabetes, 25% infarto agudo do miocárdio prévio e 42% apresentaram-se com síndrome coronária aguda. A maioria das lesões (69%) era de elevada complexidade(ACC/AHA tipo B2/C). As médias da extensão e do diâmetro nominais dos stents foram, respectivamente, 19,9 ± 5,3 mm e 3,0 ± 0,4 mm. Os sucessos angiográfico e de procedimento foram de 99,7 e 98%, respectivamente. Aos 12 meses, a taxa cumulativa de eventos cardíacos adversos maiores, disponível em 100% dos pacientes, foi de 5,6% (morte cardíaca: 1,3%; infarto agudo do miocárdio: 3,0%; revascularização da lesão-alvo: 2,2%). Já a trombose de stent ocorreu em cinco pacientes (0,9%), sendo reportada apenas uma ocorrência entre 6 e 12 meses. Conclusões: O stent farmacológico XIENCE V® demonstrou segurança e eficácia sustentadas ao final de 12meses no tratamento de lesões coronárias complexas em pacientes da prática diária...

The Xience VTM everolimus-eluting stents is a new generation drug-eluting stent (DES)that incorporates a low profile cobalt-chromium platform (81 m) and a highly biocompatible polymer(fluoropolymer), which carries and controls the release of everolimus. Recent studies have demonstrated sustained safety and efficacy of the Xience VTM in the treatment of real-world populations. Our aim was to report the clinical results of 12 months of the BRAVO Brazilian protocol. Methods: The BRAVO Registry was a prospective, non-randomized, single-arm, multicenter (25 centers) study that evaluated the late clinical results of 535 minimally selected patients treated with the drug eluting stent Xience VTM in Brazilian daily practice. Results: Overall, 40% of patients had diabetes, 25% prior myocardial infarction, and 42% presented with acute coronary artery syndrome. The majority of lesions (69%) was highly complex (ACC/AHA type B2 or C).The mean length and the nominal stent diameter were 19.9 ± 5.3 mm and 3.0 ± 0.4 mm, respectively.The angiographic and procedural successes were 99.7 and 98%, respectively. At 12 months, the cumulative rate of major adverse cardiac events, available in 100% of patients, was 5.6% (cardiac death: 1.3%; acute myocardial infarction: 3.0%; revascularization of the target lesion: 2.2%). Stent thrombosis occurred in 5 patients (0,9%), and only 1 case was reported between 6 and 12 months. Conclusions: The drug-eluting stent Xience V™ demonstrated sustained safety and efficacy up to 12 months in the treatment of complex coronary lesions in patients from daily practice...

Aplicações do Balão Farmacológico na Doença Arterial Coronária / Applications of the Drug-Eluting Balloon in Coronary Artery Disease

As estratégias de revascularização percutânea evoluíram significativamente nas últimas décadas. No entanto, toda nova tecnologia apresenta um benefício sobre a anterior, mas traz consigo também novos riscos. A hiperplasia neointimal, associada aos stents não farmacológicos, e a endotelização tardia das hastes e reação inflamatória vascular ao polímero, associada aos stents farmacológicos, são exemplos dessa premissa. Os balões farmacológicos foram desenvolvidos com o racional de modular a hiperplasia neointimal após a intervenção e de não suscitar os problemas tardios relacionados aos stents com eluição de fármacos antiproliferativos. No entanto, as evidências e as recomendações para sua utilização ainda não foram adequadamente definidas. Esta revisão objetiva apresentar e caracterizar os tipos de balão farmacológico disponíveis no mercado mundial, fazendo uma revisão dos estudos mais relevantes presentes na literatura sobre seu uso nos diversos cenários clínicos e descrever as principais indicações e atuais recomendações para seu uso.

Percutaneous revascularization strategies have evolved significantly in the past decades. However, every new technology has advantages over the previous ones, but also carries new risks. Neointimal hyperplasia, associated with bare metal stents, and delayed strut endothelialization and vascular inflammatory reaction to the polymer, associated with drug-eluting stents, are examples of this premise. Drug-eluting balloons were developed with the aim to modulate neointimal hyperplasia after intervention, avoiding the late risks associated with drug-eluting stents. However, the evidence and recommendations for their use have not been adequately defined. This review aims to present and characterize the different types of drug-eluting balloons commercially available worldwide, reviewing the most relevant studies in the literature in different clinical scenarios and describe the main indications and recommendations for their use.

Stable angina and ST-segment depression: diagnostic value in patients undergoing coronary angiography.

BACKGROUND: Clinical history and exercise testing (ET) are the main methods used to screen for coronary artery disease (CAD). Correct interpretation of such data is essential in determining diagnostic and treatment strategies. OBJECTIVE: To assess the diagnostic value of stable angina (SA) and ET in patients with suspected CAD undergoing coronary angiography and to compare results between the sexes. METHODS: We assessed 62 patients undergoing coronary angiography; ET was performed in 54 of them, being considered positive for ischemia in cases of ST-segment depression of > or =1 mm. The coronary angiograms were analyzed by two observers and patients were divided into two groups depending on the severity of CAD: Group 1: > or =70% stenosis (n=26), and Group 2: <70% stenosis (n=36). RESULTS: The patients' mean age was 58+/-9 years, and 55% were male. SA was found in 24% of cases and ET was positive for ischemia in 53%. SA showed a sensitivity of 46.1%, specificity 91.7%, positive predictive value (PPV) 80%, negative predictive value (NPV) 70%, positive likelihood ratio (LR+) 5.1 and negative likelihood ratio (LR-) 0.6, while the corresponding results for ET were sensitivity of 70.8%, specificity 60%, PPV 59%, NPV 72%, LR+ 1.75 and LR- 0.5. SA was shown to have a greater NPV in women, and the LR+ was also significantly higher in women. CONCLUSION: SA was shown to be a good diagnostic marker, with high specificity and PPV. The greater NPV and LR+ in women was shown to be superior for post-test prediction of angina. ET results were similar for both sexes and showed similar sensitivity and specificity to that reported in the literature.

Aneurisma ilíaco associado a fístula arteriovenosa / Iliac aneurysm associated with arteriovenous fistula / Iliac aneurysm associated with arteriovenous fistula

A ruptura dos aneurismas aorto-ilíacos para a veia ilíaca ou veia cava é uma complicação pouco comum. A hipertensão venosa leva a vários sinais e sintomas, o que dificulta o diagnóstico pré-operatório, tais como edema do membro inferior, dispnéia, hematúria, sinais de insuficiência renal ou cardíaca. Sopro abdominal é a chave do diagnóstico clínico, associado à massa pulsátil e dor abdominal. O reconhecimento da fístula arteriovenosa no pré-operatório é importante para o planejamento cirúrgico. Relatamos um caso de aneurisma da artéria ilíaca comum e interna direita associado a fístula para veia ilíaca comum, cursando, inicialmente, com edema do membro inferior direito e dispnéia, o que levou ao diagnóstico incorreto de trombose venosa profunda.

Rupture of aortoiliac aneurysms into the iliac vein or vena cava is an uncommon complication. Many signs and symptoms develop as a result of venous hypertension, which makes preoperative diagnosis difficult, such as leg edema, dyspnea, hematuria, signs of renal or cardiac insufficiency. Abdominal bruit, associated with pulsatile mass and abdominal pain, is the key for clinical diagnosis. Preoperative recognition of arteriovenous fistula is important for surgical planning. We report a case of right internal and common iliac artery aneurysm associated with fistula into the common iliac vein. Initial symptoms were right leg edema and dyspnea, which induced to the incorrect diagnosis of deep vein thrombosis.

[Carotid intimal-medial thickening and endothelial function in coronary artery disease]. / Espessamento médio-intimal da carótida e função endotelial na doença arterial coronariana.

OBJECTIVE: To investigate the correlation between the endothelial function and the carotid intimal-medial thickening (IMT) in a population of patients with coronary artery disease, as well as that between the endothelial function and carotid IMT with the severity of the coronary lesions. METHODS: Forty-three patients aged 60.5+/-9.2 years, (67.4% males) with coronary artery disease at the coronariography were studied. Endothelial function was assessed using the brachial artery reactivity test (BART), which measured the percentage of flow-mediated dilatation (%FMD). The carotid IMT was evaluated through vascular ultrasound. RESULTS: The mean %FDM was 4.7 +/- 3.6 and the mean carotid IMT was 1.08 +/- 0.23 mm. The carotid MIT and %FMD measurements showed a statistically significant correlation, with Spearmans coefficient of 0.315, p= 0.042, demonstrating that lower %FMD values corresponded to an increased carotid IMT (r = -0.315, p = 0.042). There was no correlation between %FMD or IMT and the severity of coronary lesions. CONCLUSIONS: The presence of a correlation between carotid IMT and %FMD demonstrates a concomitance of anatomical and functional vascular alterations in coronary artery disease, regardless of the severity of the atherosclerotic lesions.

Espessamento médio-intimal da carótida e função endotelial na doença arterial coronariana / Carotid intimal-medial thickening and endothelial function in coronary artery disease

OBJETIVO: Investigar uma correlação entre o teste de reatividade da artéria braquial (BART) e o espessamento médio-intimal (EMI) da carótida em uma população de pacientes com doença arterial coronariana, assim como avaliar uma correlação do BART e do EMI da carótida com a gravidade da doença arterial coronariana demonstrada através da coronariografia. MÉTODOS: Quarenta e dois pacientes (idade: 60,7 ± 9,2 anos, 66,7 por cento do sexo masculino) com doença arterial coronariana por coronariografia foram estudados. A função endotelial foi avaliada de modo não-invasivo através do BART, quando foi medido o porcentual de dilatação mediada pelo fluxo ( por centoDMF). O EMI de carótida foi avaliado por meio de ultra-som vascular. RESULTADOS: A média de por centoDMF foi de 4,7 ± 3,6 e a média de EMI de carótida foi de 1,08 ± 0,23 mm. As medidas do EMI de carótida e do por centoDMF apresentaram correlação estatisticamente significativa, com coeficiente de Spearman de -0,315, valor p = 0,042, demonstrando que valores menores de por centoDMF se correlacionaram a um maior EMI de carótida. Não houve correlação entre por centoDMF, EMI e a gravidade das lesões; CONCLUSÃO: A presença de uma correlação entre o por centoDMF e o EMI da carótida demonstra a concomitância de alterações vasculares funcionais e anatômicas na doença arterial coronariana, independentemente da gravidade das lesões ateroscleróticas.

Encephalopathy after distal splenorenal shunt in schistosomiasis: surgical treatment by ligation of collateral circulation

A anastomose esplenorenal distal e a melhor alternativa para a prevençäo da hemorragia em esquistossomoticos que sangram devido hipertensäo portal. Baseado na experiência anastomose esplenorenal distal de que apenas pequeno grupo destes pacientes desenvolve encefalopatia portosistemica no pós-operatorio da anastomose esplenorenal distal...